GLP-1 Receptor Agonist Class / Incretin Mimetic Research Compounds
GLP-1 Receptor Agonist Research Compounds — Class Overview
GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists) are a structurally diverse class of peptide research compounds that activate the GLP-1 receptor (GLP-1R) — a class B GPCR expressed in pancreatic β-cells, hypothalamus, brainstem, heart, kidneys, and other tissues. This class includes semaglutide, tirzepatide (dual GIP/GLP-1R agonist), liraglutide, and retatrutide (triple agonist), representing the most active area of metabolic disease and obesity pharmacology research of the 2020s.
Compound identity
- Name
- GLP-1 Receptor Agonists (Research Overview)
- Class
- GLP-1 Receptor Agonist Class / Incretin Mimetic Research Compounds
- Also known as
- Ozempic peptide, GLP-1 agonist research, semaglutide tirzepatide liraglutide, GLP-1 research compound, GLP-1 receptor agonist class, incretin mimetic peptide, buy GLP-1 peptide
Research context
The GLP-1 receptor (GLP-1R) is a class B secretin-family GPCR activated by native GLP-1(7-36)NH₂ and GLP-1(7-37), peptide fragments derived from proglucagon processing in intestinal L-cells. GLP-1R signals primarily through Gαs-coupled adenylyl cyclase (↑cAMP), activating PKA and EPAC2 downstream, as well as Gαq/11 (↑IP₃/DAG) and β-arrestin-dependent pathways (receptor internalization). In pancreatic β-cells, GLP-1R activation potentiates glucose-stimulated insulin secretion (GSIS) via cAMP/PKA-dependent augmentation of KATP channel closure and calcium influx. In the hypothalamus and brainstem, GLP-1R signaling reduces food intake and regulates energy homeostasis via arcuate nucleus (ARC), dorsomedial hypothalamus (DMH), and nucleus tractus solitarius (NTS) circuits. The cardiovascular GLP-1R (cardiomyocytes, endothelium) mediates cardioprotective effects via PI3K/Akt and eNOS pathways. GLP-1R is also expressed in liver, kidney tubules, lung, and immune cells, making it a pleiotropic target for research across multiple disease biology areas. The class B GPCR structural biology of GLP-1R — including solved cryo-EM structures of GLP-1R bound to GLP-1 agonists, Gs protein, and β-arrestin — has provided a detailed molecular framework for receptor pharmacology research.
DMV Research supplies three GLP-1 axis research compounds covering the pharmacological spectrum of the class. Semaglutide (CAS 910463-68-2, MW 4113.58 Da) is a 31-aa GLP-1 monoagonist with Aib8 substitution (full DPP-4 resistance), C18 fatty diacid conjugated via OEG-OEG-γGlu linker to Lys26 (albumin binding), and a ~7-day half-life — the longest-acting commercial GLP-1 analog and the compound studied in the SUSTAIN/PIONEER/SELECT trial programs. Tirzepatide (CAS 2023788-19-2, MW 4813.47 Da) is a 39-aa dual GIP/GLP-1R agonist (the 'twincretin'), acting on both GIPR (at GIP agonist potency) and GLP-1R (at EC₅₀ below semaglutide affinity) — studied in the SURPASS/SURMOUNT programs showing superior weight loss vs monoagonists. Liraglutide (CAS 204656-20-2, MW 3751.20 Da) is the earlier-generation GLP-1 monoagonist with C16 fatty acid (palmitic acid) via Glu linker, ~13h half-life, and the pharmacological reference standard against which newer GLP-1 axis compounds are compared. Additionally, Retatrutide (CAS 2381089-83-2) is a triple agonist at GLP-1R + GIPR + GCGR (glucagon receptor) — the GLP-3 axis compound representing the next-generation direction in metabolic pharmacology research.
Research applications for GLP-1 receptor agonists span multiple domains. In β-cell biology: GSIS potentiation, β-cell proliferation (GLP-1R activates pro-mitotic EPAC2/ERK signaling), β-cell survival under glucolipotoxicity. In obesity/energy balance: hypothalamic appetite suppression, brainstem NTS satiety signaling, adipose tissue lipolysis. In cardiovascular research: LEADER (liraglutide), SUSTAIN-6/SELECT (semaglutide), and SURMOUNT-Heart (tirzepatide) trial mechanism-of-action research — GLP-1R cardioprotection, blood pressure reduction, anti-inflammatory vascular effects. In neurodegeneration: GLP-1R agonists are studied in Parkinson's disease (LIXIPARK trial with liraglutide; NLY01/semaglutide), Alzheimer's disease, and neuroprotection models. In NAFLD/NASH: hepatic GLP-1R-mediated lipid metabolism effects (studied in LEAN, NASH resolution trials). DMV Research supplies each GLP-1 axis compound as a lyophilized peptide with per-batch Certificate of Analysis confirming identity by mass spectrometry and purity ≥99% by HPLC.
Frequently asked questions
What are GLP-1 receptor agonists?+
GLP-1 receptor agonists are a class of peptide compounds that activate the GLP-1 receptor (GLP-1R), a class B GPCR expressed in pancreatic β-cells, hypothalamus, gut, heart, kidneys, and other tissues. Endogenous GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food intake, acting to potentiate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. Research-grade GLP-1 agonists include semaglutide (MW 4113 Da, ~7d half-life), tirzepatide (dual GIP/GLP-1R, MW 4813 Da), liraglutide (MW 3751 Da, ~13h half-life), and retatrutide (triple GLP-1R/GIPR/GCGR agonist). All are supplied by DMV Research for research use only.
What is the relationship between Ozempic and semaglutide?+
Semaglutide is the active pharmaceutical ingredient (API) in Ozempic (subcutaneous injection, type 2 diabetes) and Wegovy (higher-dose subcutaneous, obesity). The peptide compound semaglutide (CAS 910463-68-2, MW 4113.58 Da) is a 31-amino acid GLP-1 receptor agonist with an Aib8 substitution (DPP-4 resistance) and a C18 fatty diacid chain conjugated via a tripartite OEG-OEG-γGlu linker to Lys26, enabling albumin binding and a ~7-day half-life. As a research compound supplied by DMV Research, semaglutide is the peptide molecule — identical in structure to the API in FDA-approved medications — for in-vitro and pre-clinical laboratory research use only, not for human consumption.
How does tirzepatide differ from semaglutide in GLP-1R research?+
Tirzepatide (dual GIP/GLP-1 agonist, 'twincretin', MW 4813 Da) acts on two receptors simultaneously — GIP receptor (GIPR, primary scaffold) and GLP-1 receptor (GLP-1R, lower EC₅₀ than native GLP-1). Semaglutide is a monoagonist acting selectively on GLP-1R. Research differences: tirzepatide produced greater weight loss in SURMOUNT-1 (20.9% at max dose) vs semaglutide in STEP-1 (14.9%) — likely from additive GIPR + GLP-1R signaling. GIPR is expressed in adipocytes, hypothalamus, and GIP-secreting K-cells; GIPR agonism may enhance insulin sensitivity and fat mobilization effects beyond pure GLP-1R activation. In research pharmacology: the GIP/GLP-1 dual agonism allows dissection of receptor-specific vs additive signaling in metabolic biology.
Which GLP-1 research compound should I use for β-cell research?+
All three GLP-1 agonists at DMV Research are used in β-cell biology, differing in half-life and receptor selectivity. Liraglutide (~13h half-life) is the established reference standard — decades of published mechanistic data in MIN6, INS-1E, isolated islets, and in-vivo rodent models. Semaglutide (~7d half-life, strongest albumin binding) is preferred for in-vivo models requiring less frequent dosing and for research directly translatable to Ozempic/Wegovy pharmacology. Tirzepatide is used when the GIP receptor axis contribution to β-cell biology is the research question — additive GIPR + GLP-1R effects on GSIS, β-cell proliferation, and glucagon suppression. For pure GLP-1R pharmacology without GIP confounding, monoagonists (liraglutide, semaglutide) are the correct choice.
Research use only
All products are intended for laboratory and research use only (RUO) and are not for human consumption, ingestion, or any in-vivo use.
The statements on this page have not been evaluated by the FDA. GLP-1 Receptor Agonists (Research Overview) is not intended to diagnose, treat, cure, or prevent any disease. Content is provided for laboratory research reference only.